Vaxcyte, Inc. (NASDAQ:PCVX) Receives $147.50 Consensus Target Price from Analysts

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has earned an average recommendation of "Buy" from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have covered the stock in the last year is $147.50.

Several equities research analysts have recently weighed in on the stock. Guggenheim reissued a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Needham & Company LLC reissued a "buy" rating and set a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, December 20th. They set a "buy" rating and a $135.00 price target on the stock.

Insider Transactions at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the completion of the sale, the chief financial officer now directly owns 109,491 shares of the company's stock, valued at $9,472,066.41. This trade represents a 6.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the company's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now owns 7,175 shares of the company's stock, valued at approximately $610,664.25. This trade represents a 46.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 46,250 shares of company stock valued at $3,840,018 over the last ninety days. Corporate insiders own 3.10% of the company's stock.

Remove Ads

Hedge Funds Weigh In On Vaxcyte

A number of institutional investors have recently modified their holdings of PCVX. CIBC Asset Management Inc raised its holdings in Vaxcyte by 3.6% in the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company's stock valued at $358,000 after acquiring an additional 110 shares in the last quarter. Bridgefront Capital LLC increased its stake in shares of Vaxcyte by 4.2% in the fourth quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock valued at $347,000 after buying an additional 172 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after purchasing an additional 260 shares in the last quarter. Catalyst Funds Management Pty Ltd raised its position in shares of Vaxcyte by 1.7% during the fourth quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company's stock worth $1,506,000 after acquiring an additional 300 shares during the last quarter. Finally, Whipplewood Advisors LLC acquired a new stake in shares of Vaxcyte during the 4th quarter worth approximately $28,000. Institutional investors own 96.78% of the company's stock.

Vaxcyte Trading Down 2.6 %

Shares of PCVX traded down $1.92 during mid-day trading on Friday, reaching $71.90. The company had a trading volume of 727,046 shares, compared to its average volume of 935,023. The stock has a market cap of $9.26 billion, a price-to-earnings ratio of -15.63 and a beta of 1.02. The firm has a fifty day simple moving average of $81.26 and a 200-day simple moving average of $93.61. Vaxcyte has a fifty-two week low of $58.10 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. As a group, equities analysts predict that Vaxcyte will post -4.21 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.